Christopher Cannon, MD
Interventional Cardiology · Medford, ORNPI 1487650586
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,680 of the $7,195 with a category attached, or 65.1%. It is spread thinly across 28 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2019 at $3,055 and has fallen 98.5% since, to $45 in 2025.
Across 193 payments — averaging $37.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Terumo Medical Corporation$1K
- Medical Device Business Services, Inc.$1K
- Abbott$454
- Johnson & Johnson$407
- Pfizer$326
- plus $2K from 22 others
What the payments were for
- Travel & lodging$2,51435%
- Food & beverage$4,68065%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 35 | $1,688 |
| Terumo Medical Corporation | 9 | $1,301 |
| Medical Device Business Services, Inc. | 8 | $1,063 |
| Abbott | 7 | $454 |
| Johnson & Johnson | 23 | $407 |
| Pfizer | 15 | $326 |
| Heartflow, Inc. | 9 | $272 |
| E.r. Squibb & Sons, L.L.C. | 11 | $224 |
| Sanofi-aventis U.S. LLC | 10 | $202 |
| Boston Scientific | 10 | $184 |
| Philips North America LLC | 9 | $175 |
| Novartis | 7 | $151 |
| Amgen | 5 | $124 |
| AstraZeneca | 6 | $100 |
| Boehringer Ingelheim | 4 | $68 |
| Cardiovascular Systems Inc. | 5 | $64 |
| Merck | 3 | $55 |
| Lundbeck LLC | 3 | $52 |
| Angiodynamics, Inc. | 1 | $52 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Cardiva Medical, Inc. | 1 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| Novo Nordisk | 1 | $24 |
| Biosense Webster, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Inari Medical, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Navicross$1,077
- Carto 3 System$1,000
- Glidesheath$809
- GlideWire$809
- HawkOne$255
- MitraClip System$154
- Quadra Assura CRT Defibrillator$153
- FFRct$130
How this compares
$7,195 in reported general payments places this provider in the 60th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $109,594 |
| XareltoRivaroxaban | 25 | $44,011 |
| EntrestoSacubitril/Valsartan | 21 | $29,052 |
| Repatha SureclickEvolocumab | 14 | $12,588 |
| Atorvastatin Calcium | 208 | $1,550 |
| ClopidogrelClopidogrel Bisulfate | 134 | $1,295 |
| Metoprolol Succinate | 145 | $1,281 |
| Ezetimibe | 25 | $901 |
| Losartan Potassium | 107 | $850 |
| Carvedilol | 82 | $824 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 35 | $810 |
| Furosemide | 108 | $759 |
| Metoprolol Tartrate | 93 | $629 |
| Rosuvastatin Calcium | 64 | $550 |
| Amlodipine Besylate | 87 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $326 | $109,59478 claims |
| Johnson & JohnsonXarelto | $407 | $44,01125 claims |
| NovartisEntresto | $151 | $29,05221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Medford
- Tushar TulianiMedford$10K
- Alyssa CorleyMedford$9K
- Rohit MalhotraMedford$4K
- Kent DautermanMedford$2K
- Jaekyoung HongMedford$2K
- Mark MoranMedford$1K
- Roger DreilingMedford$856
- Jason WollmuthPortland$749K
- Saurabh GuptaBend$550K
- Ethan KorngoldPortland$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.